SYNTHESIS AND ANTI-DIABETIC ACTIVITY OF SOME ARYLOXYPROPANOLAMINE DERIVATIVES

摘要

Aryloxypropanolamine plays an important role in several biological activities. It shows multiple actions such as |3-blocking, anxiolytic, antihypertensive and inhibition of cytochrome p450. A series of ten aryloxypropanolamine derivatives 6a-6j were synthesized and evaluated for anti-diabetic activity. Two compounds 6b to 6g have shown good anti-diabetic activity. All synthesized compounds (6a-6j) were evaluated for their anti-diabetic activity in STZ induced diabetes model of Wistar rats. Approximately 100 million people worldwide suffer from type II diabetes (NIDDM), which is characterized by hyperglycemia due to excessive hepatic production of glucose. Noninsulin dependent Diabetes mellitus(NIDDM type II diabetes) is chronic metabolic disease characterized by insulin resistance hyperglycemia. The term diabetes mellitus describes a metabolic disorder of multiple an etiologies characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. The aryloxypropanolamines were first described as beta 3 adrenergic receptor agonist in the mid1980s. Later on several pharmaceutical industries are engaged in developing potent selective beta 3 adrenergic receptor agonist for the treatment of type II diabetes and obesity. Aryloxypropanolamines are now a days playing a very important role as an anti-diabetic agents as well as anti-obesity agent, anti-hypertensive, anti-convulsants and in cardiovascular diseases.